Treating hepatitis C in the elderly: The future is near?

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 14, 2014, Pages 2019-2028

  Conti, Fabio ^a   Vitale, Giovanni ^a   Andreone, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aged; Antiviral treatment; Elderly; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; GERIATRIC PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; LIFE EXPECTANCY; MEDICAL PRACTICE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); PATIENT CARE; PATIENT DECISION MAKING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MEDICATION ADHERENCE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84907043631     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.945422     Document Type: Review

References (64)

1. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90(10):1562-9
2. Armstrong GL,Alter MJ,McQuillan GM,et al, The past incidence of he patitis C infection: implications for the future burden of chronic liver disease in the United States, Hepatology, 2000, 31, 777-82.
3. D'Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C cirrhosis in elderly Asian patients infected during childhood. Clin Gastroenterol Hepatol 2005;3:840-2
4. Davis GL, Alter MJ, El-Serag H, et al. Aging of the hepatitis C virus (HCV)-infecte d persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21
5. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiolo gy of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
6. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945- 1965: recommendations from the centers for disease control and prevention. Ann Intern Med 2012;157:817-22
7. Okayama A, Stuver SO, Tabor E, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002;9:43-51
8. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distributio n of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11
9. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;6(5 Suppl 1):S35-46
10. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(5 Suppl 1):S47-56
11. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004;10(2 Suppl):S21-9
12. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol 2010;9(Suppl):119-22
13. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80
14. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C infection. Hepatology 2001;34:809-16
15. Zanni F, Vescovini R, Biasini C, et al. Marked increase with age of type I cytokines within memory and effector/cytotoxic CD8+ T cells in humans: a contribution to understand the relation ship between inflammation and immunosenescence. Exp Gerontol 2003;38:981-7
16. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101(6):1260-7
17. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9
18. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotype 1b is a major risk factor for the development of hepatocellular carcinoma (HCC) in cirrhotic patients: a prospective study. Hepatology 1997;25:754-8
19. Villa E, Vukotic R, Camm-A C, et al. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One 2012;7:e44624
20. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50
21. Ben Yehuda A, Globerson A, Krichevsky S, et al. Ageing and the mismatch repair system. Mech Ageing Dev 2000;121:173-9
22. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007;50(1):16-23.
23. Morgan TR,Ghany MG,Kim H-Y,et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52, 3, 833-44.
24. Backus LI, Booth royd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-16
25. Gramenzi A, Conti F, Camm-A C, et al. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis 2012;44(8):674-80
26. Kanwal F, Schnitzler MS, Bacon BR, et al. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010;153:231-9
27. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63
28. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribav irin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993-9
29. Antonucci G, Longo MA, Angeletti C, et al. The e ffect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007;102(7):1383-91
30. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010;30(4):527-37
31. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010;201(5):751-9
32. Kainuma M, Fur usyo N, Kajiwara E, et al. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010;16(35):4400-9
33. Oze T, Hiramatsu N, Yakushij in T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011;54(4):604-11
34. Nishikawa H, I guchi E, Koshikawa Y, et al. The effect of pegylated interferonalpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012;5:135
35. Kim HI, Kim IH, Jeon BJ, et al. Treatment response and tolerability of pegylated interferon-A plus ribavirin combination therapy in elderly patients (‡ 65 years) with chronic hepatitis C in korea. Hepat Mon 2012;12(7):430-6
36. Yu JW, Sun LJ, Kang P, et al. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2012;11(2):185-92 37.
37. Hu CC, Lin CL, Kuo YL, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013;37(1):81-90
38. H-ezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
39. McHutchison JG, Everso n GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
40. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
41. Jacobson IM, McHutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
42. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
43. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24
44. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicen tre phase 2 trial. Lancet 2010;376:705-16.
45. Poordad F,Mccone Jr. J.,Bacon BR,et al, Boceprevir for untreated chronic HCV genotype 1 infection,N Engl J Med, 2011, 364, 1195-206.
46. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
47. Chen EY, Sclair SN, Czul F, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol 2013;11(8):1014-20
48. Fujino H, Imamura M, Nagaoki Y, et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol 2013. [Epub ahead of print]
49. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013;59(2):205-12
50. Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014;39(1):93-103
51. Colombo M, Ferná ndez I, Abdurakhmanov D, et al. Safety and ontreatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2014;63(7):1150-8
52. H-ezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59(3):434-41
53. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162:405-12
54. The most current version of the HCV Guidance exists on recommendations for testing, managing, and treating Hepatitis C. 2014. Available from: http://www.hcvguidelines.org
55. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014. [Epub ahead of print]
56. Manns M, Marcellin P, Poordad FP, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014. [Epub ahead of print]
57. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepat itis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014. [Epub ahead of print]
58. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with Peginterferon and Ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146( 7):1669-79
59. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878- 87
60. Jac obson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867 -77
61. Mangia A, Kugelmas M, Everson G, et al. Virologic response rates to Sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data [abstract 1115]. Annual Meeting of the America n Association for the Study of Liver Diseases; 2013
62. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92
63. Cha yama K, Suzuki Y, Ikeda K, et al. All-oral combination of Daclatasvir plus Asunaprevir in interferon ineligible naive/intolerant and non responder japanese patients chronically infected with HCV genotype 1b: results from a phase 3 trial [abst ract 211]. Annual Meeting of the American Association for the Study of Liver Diseases; Washington; 2013
64. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705